Cipher Pharmaceuticals Inc

Type: Company
Name: Cipher Pharmaceuticals Inc
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Cipher to host Q2 results call July 30

Mr. Norm Evans reportsNOTICE OF CIPHER PHARMACEUTICALS INC. Q2 2014 CONFERENCE CALLCipher Pharmaceuticals Inc. will host a conference call for its second quarter 2014 financial results onWednesday, July 30, 2014.Second quarter 2014 conference callWhen: ... [Published Stockwatch - Jul 16 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Novadaq and Cipher make biotech buy list

Extended CoverageThey may be high risk, but they also offer the potential for high rewards. BNN’s Pamela Ritchie talks top biotech stock picks with Douglas Loe, Healthcare and Biotechnology analyst at Euro Pacific Canada. Loe’s buy recommendations include ... [Published Business News Network - Jul 07 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

Research and Markets (http://www.researchandmarkets.com/research/vkj9fb/product_and) has announced the addition of the "" report to their offering. Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately ... [Published Individual.com - Jun 27 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Cipher Pharma names Shawn O’Brien as CEO

Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has named Shawn O’Brien as CEO, effective June 30, succeeding Larry Andrews, who announced in March that he was stepping down. Mr. O’Brien has spent the past 30 years in the pharmaceutical and biotechnology ... [Published BioPortfolio - Jun 26 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Cipher Pharmaceuticals appoints Shawn Patrick O'Brien as CEO

Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, June 26, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien has been appointed Chief Executive Officer of Cipher, effective June ... [Published TickerTech.com - Jun 26 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Investing in the Best Canadian Biotech Stocks

You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines . In this interview with The Life Sciences ... [Published Equities.com - Jun 23 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Cipher, Andrómaco ink supply agreement for isotretinoin capsules in Chile

Canada-based Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco (Andrómaco) for isotretinoin product in Chile. ... [Published PBR - News - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 1 reports

Sector Update: Healthcare; Cipher Pharmaceuticals Licenses Isotretinoin to Andromaco, Valeant Takeover Target Allergan to Review Offer

Cipher Pharmaceuticals (DND.TO): +0.7%Concordia Healthcare (CXR.TO): -2.7%Catamaran (CCT.TO): -0.9%Tekmira Pharmaceuticals (TKM.TO): +1.7%In corporate news, Cipher Pharmaceuticals has signed an agreement granting Laboratorios Andromaco the exclusive right ... [Published Nasdaq - Jun 18 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Stocks in play: Miraculins Inc.

09:55 AM EST - Cipher Pharmaceuticals Inc. : announced it has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco S.A. under which Cipher has granted Andrómaco the exclusive right to market, sell and distribute Cipher's ... [Published BayStreet.ca - Jun 18 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Cipher Pharmaceuticals completes distribution and supply agreement for isotretinoin product in Chile

Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, June 18, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco S.A. ("Andrómaco") under which ... [Published TickerTech.com - Jun 18 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Court Report - June 2014 #3

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Glenmark Generics Ltd. et al. v. Ferring, B.V.3:14-cv-00422; filed June 9, 2014 in the Eastern District of Virginia• Plaintiffs:  Glenmark Generics Ltd.; ... [Published JD Supra - Jun 16 2014]

Quotes

...a company that is as well positioned as Cipher, with increasing revenue, a strong balance sheet, and experienced core team," said Shawn O'Brien. "I'm very excited by the opportunity to build on these strengths and help execute the growth plan."
"Extending the reach of our isotretinoin product is one of our growth priorities, and we believe Andrómaco is an excellent partner to bring this product to market in Chile" Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals
Declaratory judgment of unenforceability of U S Patent No. 7,022,340 ( "Pharmaceutical Composition as Solid Dosage Form and Method for Manufacturing Thereof" issued April 4, 2006) in conjunction with Glenmark's Paragraph IV certification as part of its filing of an ANDA to manufacture a generic version of...

More Content

All (12) | News (11) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cipher to host Q2 results call July 30 [Published Stockwatch - Jul 16 2014]
Novadaq and Cipher make biotech buy list [Published Business News Network - Jul 07 2014]
Product and Pipeline Analysis of the Global The... [Published Individual.com - Jun 27 2014]
Cipher Pharma names Shawn O’Brien as CEO [Published BioPortfolio - Jun 26 2014]
Cipher Pharmaceuticals appoints Shawn Patrick O... [Published TickerTech.com - Jun 26 2014]
Investing in the Best Canadian Biotech Stocks [Published Equities.com - Jun 23 2014]
Cipher, Andrómaco ink supply agreement for isot... [Published PBR - News - Jun 19 2014]
Sector Update: Healthcare; Cipher Pharmaceutica... [Published Nasdaq - Jun 18 2014]
Stocks in play: Miraculins Inc. [Published BayStreet.ca - Jun 18 2014]
Cipher Pharmaceuticals completes distribution a... [Published TickerTech.com - Jun 18 2014]
Court Report - June 2014 #3 [Published JD Supra - Jun 16 2014]
Ranbaxy gets US approval to launch Absorica [Published Topnews.in - May 30 2012]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cipher, Andrómaco ink supply agreement for isot... [Published PBR - News - Jun 19 2014]
Canada-based Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Laboratorios Andrómaco (Andrómaco) for isotretinoin product in Chile. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.